查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970950

无乳糖婴儿配方奶粉市场－全球产业规模、份额、趋势、机会和预测（按产品类型、销售管道、地区和竞争格局划分，2021-2031年）

Lactose-free Infant Formula Market - Global Industry Size, Share, Trends, Opportunity and Forecast, By Product Type, By Sales Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球无乳糖婴儿奶粉市场预计将从 2025 年的 212.2 亿美元成长到 2031 年的 317.2 亿美元，复合年增长率为 6.93%。

这些专门配製的母乳替代品旨在为患有次发性、原发性或先天性乳糖不耐受的婴儿提供营养，不含乳糖，而是使用蔗糖、麦芽糊精和玉米糖浆固态等替代碳水化合物。市场成长的主要驱动因素包括临床诊断的新生儿胃肠道高反应性盛行率的上升，以及职业父母对可靠且易于消化的餵食方式日益增长的需求。因此，当无法进行母乳哺育时，稳定供应安全、科学研发的替代品至关重要。

市场概览
预测期 2027-2031
市场规模：2025年 212.2亿美元
市场规模：2031年 317.2亿美元
复合年增长率：2026-2031年 6.93%
成长最快的细分市场 在线的
最大的市场 欧洲

另一方面，由于严格的法律规范和全球公共卫生倡议提倡纯母乳餵养，该行业面临巨大的阻力，这可能会限製配方奶粉的广泛应用。儘管存在这些监管障碍，该行业仍保持着巨大的经济影响力。根据欧洲特殊营养协会（Specialised Nutrition Europe）2024年的报告显示，包括婴儿奶粉奶粉在内的特殊营养品产业年销售额接近240亿欧元。这项数据凸显了针对弱势群体量身定制的特殊营养解决方案的巨大商业性价值。

市场驱动因素

次发性和先天性乳糖不耐症以及牛奶蛋白过敏的临床诊断日益增多，推动了市场成长，因为医疗需求促使人们使用特殊的营养配方奶粉。无法消化乳糖或对牛蛋白有严重反应的新生儿需要即时用氨基酸或水解蛋白配方奶粉替代正餐，以预防胃肠道併发症，从而产生了对治疗性婴儿奶粉的稳定且非週期性需求。此细分市场的规模体现在主要生产商的业绩。根据雅培公司于2024年10月发布的“2024年第三季财务业绩”，其儿童营养业务（包括消化器官系统过敏配方奶粉）在上半年实现了30.23亿美元的全球销售额。

同时，家长们日益关注动物福利和成分透明度，推动了有机和植物来源幼儿配方奶粉需求的成长，这成为重要的次要驱动因素。越来越多的家长倾向于选择天然不含乳糖的杏仁、荞麦和大豆配方奶粉，这些产品兼顾了伦理价值和消化功能需求。这一趋势使得一些小众品牌能够透过洁净标示创新来巩固自身市场地位。例如，Els Nutrition Holdings在2024年4月发布的「2023财年报告」中公布，其年销售额达到940万加元，展现了非乳製品婴幼儿营养品的商业性潜力。业界领导企业利洁时集团(Reckitt Benckiser Group PLC)的倡议也进一步印证了该领域的强劲势头。该公司在2024年2月发布的「2023财年财务业绩报告」中指出，其营养品部门的净销售额达到24.1亿英镑，凸显了其在全球范围内对婴幼儿营养管理领域的重大投资。

市场挑战

全球无乳糖婴儿奶粉市场面临的主要障碍是严格的法规环境和日益增强的倡导纯母乳哺育的公共卫生运动。这些由各国政府根据国际卫生目标实施的宣传活动，正日益限制奶粉的供应、标籤和行销，将其明确定位为次要选择而非主要选择。这种监管环境不仅限制了品牌曝光度，而且从根本上缩小了潜在基本客群，因为它强烈鼓励父母在婴儿早期关键阶段推迟或放弃使用其他替代品。

这些宣传活动的具体市场影响在关键地区持续高企的纯母乳哺育率中显而易见，直接限制了配方奶粉的潜在市场。例如，根据英国专业营养协会 (BSNA) 2024 年的报告，英格兰约有 29.3% 的婴儿在 6-8 週大时接受纯母乳哺育。这项数据表明，公共卫生讯息在影响父母的餵食选择方面卓有成效，并为新生儿期乳糖不耐受配方奶粉的广泛应用设置了永久性障碍。

市场趋势

添加人类乳寡糖 (HMO) 是该行业一项重要的技术转折点，它从单纯去除乳糖发展到积极模拟母乳复杂的免疫特性。虽然传统的无乳糖婴儿奶粉能有效预防消化器官系统问题，但它们历来缺乏在脆弱的婴儿体内培养健康肠道菌丛所需的益生元成分。因此，製造商开始在配方中添加生物同源性 HMO，例如 2'-岩藻糖基乳糖，以在不添加乳糖的情况下支持肠道屏障功能和有益菌丛。这些高价值成分的商业性成功从主要供应商的业绩中可见一斑。在 2025 年 2 月发布的「2024 年全年业绩报告」中，dsm-firmenich 公布了 127.99 亿欧元的总销售额，成长主要得益于其健康、营养与护理部门的创新主导增长，该部门正是这些先进成分的供应商。

同时，向环保永续包装的转变正在改变市场的营运结构。这主要得益于家长环保意识的增强以及监管要求淘汰新材料的推动。製造商正在逐步淘汰用于一次性营养品的传统塑胶汤匙和复合罐，转而使用生物基塑胶、完全可回收的锡和纸质包装，以减少与一次性营养品相关的碳排放。这种向循环经济原则的策略性转变，不仅意味着遵循成本，更成为一种竞争优势。正如达能在2025年3月发布的《2024财年财务报告》中所指出的，集团透过有效实施「Renew」策略，实现了4.3%的同店销售成长。该策略强调在其所有特种营养产品系列中实现环境管理和永续价值创造。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球无乳糖奶粉市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按产品类型（有机、传统）
    • 销售管道（超级市场/大卖场、便利商店、线上、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美无乳糖配料市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲无乳糖奶粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区无乳糖婴儿爽身粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲无乳糖奶粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美无乳糖配料奶市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球无乳糖奶粉市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Nestle SA
  • Ausnutria Dairy Corporation Ltd.
  • Valio Ltd
  • Abbott Laboratories
  • Bubs Australia Limited
  • Danone SA
  • Reckitt Benckiser Group PLC
  • Perrigo Company plc
  • Dana Dairy Group LTD
  • Hero AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 26725

The Global Lactose-free Infant Formula Market is projected to expand from USD 21.22 Billion in 2025 to USD 31.72 Billion by 2031, registering a CAGR of 6.93%. These specialized breast milk substitutes are engineered without lactose, utilizing alternative carbohydrates like sucrose, maltodextrin, or corn syrup solids to nourish infants suffering from secondary, primary, or congenital lactose intolerance. Market growth is fundamentally underpinned by key factors such as the growing prevalence of clinically diagnosed neonatal digestive sensitivities and the escalating need among working parents for reliable, digestible feeding options, necessitating the consistent availability of safe, scientifically developed alternatives when breastfeeding is not feasible.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.22 Billion
Market Size 2031USD 31.72 Billion
CAGR 2026-20316.93%
Fastest Growing SegmentOnline
Largest MarketEurope

Conversely, the sector encounters substantial headwinds arising from rigorous regulatory structures and global public health initiatives that champion exclusive breastfeeding, potentially limiting the broader uptake of formula products. Despite these regulatory barriers, the industry maintains a massive economic presence. As reported by Specialised Nutrition Europe in 2024, the specialized nutrition sector, which includes the infant formula category, achieved an annual turnover nearing 24 billion EUR. This statistic highlights the significant commercial impact of specialized dietary solutions tailored for vulnerable populations.

Market Driver

The escalating clinical identification of secondary and congenital lactose intolerance, coupled with cow's milk protein allergies, acts as a major engine for market growth, as medical requirements necessitate the use of specialized nutritional formulas. Newborns unable to digest lactose or those suffering severe reactions to bovine proteins demand immediate dietary replacement with amino acid or hydrolyzed protein-based formulas to avert gastrointestinal complications, creating a steady, non-cyclical demand for therapeutic infant nutrition. The financial scale of this segment is reflected in the results of major manufacturers; according to Abbott's 'Third-Quarter 2024 Results' released in October 2024, their Pediatric Nutrition division, comprising formulations for digestive sensitivities, achieved global sales of 3,023 million USD in the fiscal year's first nine months.

Concurrently, the increasing appetite for organic and plant-based formula options serves as a crucial secondary driver, fueled by parental concerns regarding animal welfare and ingredient transparency. Caregivers are increasingly favoring almond, buckwheat, or soy-based formulations that naturally lack lactose, harmonizing ethical values with functional digestive needs, a trend that has allowed niche players to gain ground through clean-label innovations. For instance, Else Nutrition Holdings Inc. reported in its 'Year End 2023 Financial Results' in April 2024 that it secured annual revenue of 9.4 million CAD, demonstrating the commercial potential of non-dairy infant nutrition. The sector's broader strength is further evidenced by industry leaders like Reckitt Benckiser Group PLC, which reported in February 2024 within its 'Full Year 2023 Results' that its Nutrition unit generated net revenue of 2,410 million GBP, highlighting significant global investment in specialized infant dietary management.

Market Challenge

A significant obstacle facing the Global Lactose-free Infant Formula Market involves strict regulatory environments and intensified public health movements that promote exclusive breastfeeding. These campaigns, aligned with international health objectives and implemented by national authorities, increasingly curtail the availability, labeling, and marketing of formula, categorizing it firmly as a secondary recourse rather than a primary option. Such a regulatory landscape not only restricts brand exposure but also fundamentally narrows the potential customer base during the crucial early stages of infancy, as parents are heavily urged to postpone or forgo the use of substitutes.

The tangible market effect of these advocacy initiatives is evident in the continued high rates of exclusive breastfeeding in major regions, which directly limits the addressable market for formula products. For example, the British Specialist Nutrition Association reported in 2024 that roughly 29.3% of infants in England were being exclusively breastfed at six to eight weeks of age. This statistic underscores the efficacy of public health messaging in shaping parental feeding choices, thereby establishing an enduring impediment to the widespread acceptance of lactose-free formula solutions during the newborn phase.

Market Trends

The incorporation of Human Milk Oligosaccharides (HMOs) marks a pivotal technological shift in the industry, evolving from mere lactose elimination to actively mimicking breast milk's complex immunological attributes. While traditional lactose-free formulas effectively prevent digestive issues, they have historically lacked the prebiotic elements needed to cultivate a healthy gut microbiome in vulnerable infants, prompting manufacturers to enrich recipes with bio-identical HMOs like 2'-Fucosyllactose to support barrier function and beneficial bacteria without adding lactose. The commercial success of integrating these high-value ingredients is clear from major supplier performance; dsm-firmenich reported in its 'Full Year 2024 Results' in February 2025 that it achieved total sales of 12,799 million EUR, largely fueled by innovation-driven growth in its Health, Nutrition & Care unit, which provides these advanced components.

In parallel, the shift toward Eco-Friendly and Sustainable Packaging is transforming the market's operational structure, driven by parental environmental awareness and regulatory mandates to abandon virgin materials. Manufacturers are progressively swapping traditional plastic scoops and composite tins for bio-based plastics, fully recyclable tinplate, and paper-based outer shells to lower the carbon emissions linked to single-use nutrition products. This strategic move towards circular economy principles is emerging as a competitive advantage rather than a mere compliance expense; as noted in Danone's 'Universal Registration Document - Annual Financial Report 2024' from March 2025, the group realized like-for-like sales growth of 4.3%, attributed to the effective implementation of its 'Renew' strategy which emphasizes environmental stewardship and sustainable value creation across its specialized nutrition range.

Key Market Players

  • Nestle S.A.
  • Ausnutria Dairy Corporation Ltd.
  • Valio Ltd
  • Abbott Laboratories
  • Bubs Australia Limited
  • Danone S.A.
  • Reckitt Benckiser Group PLC
  • Perrigo Company plc
  • Dana Dairy Group LTD
  • Hero AG

Report Scope

In this report, the Global Lactose-free Infant Formula Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lactose-free Infant Formula Market, By Product Type

  • Organic
  • Conventional

Lactose-free Infant Formula Market, By Sales Channel

  • Supermarket/Hypermarket
  • Convenience Stores
  • Online
  • Others

Lactose-free Infant Formula Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lactose-free Infant Formula Market.

Available Customizations:

Global Lactose-free Infant Formula Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lactose-free Infant Formula Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Organic, Conventional)
    • 5.2.2. By Sales Channel (Supermarket/Hypermarket, Convenience Stores, Online, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Lactose-free Infant Formula Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Sales Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lactose-free Infant Formula Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Sales Channel
    • 6.3.2. Canada Lactose-free Infant Formula Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Sales Channel
    • 6.3.3. Mexico Lactose-free Infant Formula Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Sales Channel

7. Europe Lactose-free Infant Formula Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Sales Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lactose-free Infant Formula Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Sales Channel
    • 7.3.2. France Lactose-free Infant Formula Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Sales Channel
    • 7.3.3. United Kingdom Lactose-free Infant Formula Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Sales Channel
    • 7.3.4. Italy Lactose-free Infant Formula Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Sales Channel
    • 7.3.5. Spain Lactose-free Infant Formula Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Sales Channel

8. Asia Pacific Lactose-free Infant Formula Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Sales Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lactose-free Infant Formula Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Sales Channel
    • 8.3.2. India Lactose-free Infant Formula Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Sales Channel
    • 8.3.3. Japan Lactose-free Infant Formula Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Sales Channel
    • 8.3.4. South Korea Lactose-free Infant Formula Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Sales Channel
    • 8.3.5. Australia Lactose-free Infant Formula Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Sales Channel

9. Middle East & Africa Lactose-free Infant Formula Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Sales Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lactose-free Infant Formula Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Sales Channel
    • 9.3.2. UAE Lactose-free Infant Formula Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Sales Channel
    • 9.3.3. South Africa Lactose-free Infant Formula Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Sales Channel

10. South America Lactose-free Infant Formula Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Sales Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lactose-free Infant Formula Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Sales Channel
    • 10.3.2. Colombia Lactose-free Infant Formula Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Sales Channel
    • 10.3.3. Argentina Lactose-free Infant Formula Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Sales Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lactose-free Infant Formula Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Nestle S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ausnutria Dairy Corporation Ltd.
  • 15.3. Valio Ltd
  • 15.4. Abbott Laboratories
  • 15.5. Bubs Australia Limited
  • 15.6. Danone S.A.
  • 15.7. Reckitt Benckiser Group PLC
  • 15.8. Perrigo Company plc
  • 15.9. Dana Dairy Group LTD
  • 15.10. Hero AG

16. Strategic Recommendations

17. About Us & Disclaimer